跳至主要内容
临床试验/NL-OMON55165
NL-OMON55165已完成2 期

Optical coherence tomography-guided PCI with single antiplatelet therapy - OPTICA

Academisch Medisch Centrum0 个研究点目标入组 75 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >=18 years
  • - NSTE-ACS diagnosis in accordance with relevant guidelines
  • - *De novo* coronary lesion(s) eligible for PCI using new generation
  • drug-eluting stent and requiring revascularization according to relevant
  • - Written informed consent

排除标准

  • - Known allergy or contraindication for prasugrel or ticagrelor use
  • - Concurrent use of oral anticoagulants (e.g. for atrial fibrillation)
  • - Overwriting indication for DAPT (e.g. recent PCI or ACS)
  • - Planned surgical intervention within 12 months of planned
  • revascularization
  • - PCI of left main disease, chronic total occlusion, bifurcation lesion
  • requiring two-stent treatment, saphenous or arterial graft lesion, severely
  • calcified lesions
  • - Recent or ongoing treatment with a strong CYP3A4 inhibitor or inducer
  • - Pregnant or breastfeeding women at time of enrolment
  • - Participation in another trial with an investigational drug or device (i.e.

研究者

相似试验